Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

In a meta-analysis, topical Janus kinase (JAK) inhibitors demonstrated promising but non-significant results for vitiligo, with patients administered JAK inhibitors having a higher likelihood of ...

Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin repigmentation in people with vitiligo, paving the way for additional oral and topical JAK inhibitors to treat this autoimmune ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

Eosinophilic cellulitis seems to be a type 2 inflammatory disease, with preferential activation of the Janus kinase (JAK)1/JAK2-signal transducer and activator of transcription (STAT)5 pathways, ...

Higher doses of a novel Janus kinase inhibitor were associated with improved response over 24 weeks in a cohort of patients with alopecia areata, according to a study. Brett King, MD, PhD, of the ...

Inflammatory cytokines play a major role in the pathogenesis of immune-mediated chronic inflammatory diseases. Cytokines are rarely produced alone and play their role in a complex network with others.

The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling. Since this time, more than 2,500 articles have ...